

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.7619 mL	8.8093 mL	17.6187 mL
5 mM	0.3524 mL	1.7619 mL	3.5237 mL
10 mM	0.1762 mL	0.8809 mL	1.7619 mL
50 mM	0.0352 mL	0.1762 mL	0.3524 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Peter G. Smith, et al. Abstract DDT01-04: Discovery and development of H3B-6545: A novel, oral, selective estrogen receptor covalent antagonist (SERCA) for the treatment of breast cancer. AACR Annual Meeting 2017; April 1-5.

Manav Korpai, et al. Development of a First-in-Class Oral Selective ER Covalent Antagonist (SERCA) for the Treatment of ER α

Furman C, et al. Covalent ER α Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer. Mol Cancer Ther. 2022 Jun 1;21(6):890-902.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481